PRME
Prime Medicine, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+10/100
Last price
3.42
▲ 0.21 (6.43%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.45
Prev close
3.21
Day high
3.72
Day low
3.26
Volume
12.02M
Market cap
$634.82M
P/E (TTM)
—
52W range
2.67 – 6.85
Day trading desk
Gap from prior close
+7.48%
Prior close 3.21
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
1.17%
3.41 – 3.45
Position in range
16%
Near session low
ATR (14D)
0.28
8.22% of price
Prior day high
3.26
PDH
Prior day low
2.88
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 3.18M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+13.27%
+11.3%
1M
-5.41%
-6.6%
3M
-24.24%
-28.8%
6M
+2.64%
-15.5%
YTD
+0.86%
-13.4%
1Y
-44.62%
-61.0%
3Y
-63.31%
-145.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PRME open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
36.11M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 1, 25 | NELSEN ROBERT TAYLOR Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 3.03M | $10.00M | Indirect |
| Aug 1, 25 | ARCH VENTURE PARTNERS X LLC Beneficial Owner of more than 10% of a Class of Security |
BUY | 3.03M | $10.00M | Indirect |
| Aug 1, 25 | GV 2021 GP, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.50M | $4.95M | Indirect |
| Jun 30, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $52.83K | Direct |
| Jun 23, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $45.40K | Direct |
| Jun 16, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $31.20K | Direct |
| Jun 11, 25 | LIU DAVID R Beneficial Owner of more than 10% of a Class of Security |
BUY | 21.00K | $33.59K | Direct |
| May 21, 25 | REINE ALLAN Chief Executive Officer |
BUY | 125.00K | $147.15K | Direct |
| May 21, 25 | LEE ANN LOUISE Officer |
BUY | 100.00K | $113.00K | Direct |
| May 20, 25 | BRUDNICK RICHARD Officer |
BUY | 20.00K | $23.79K | Direct |
| Oct 8, 24 | GOTTESDIENER KEITH MICHAEL Chief Executive Officer |
STOCK | 226.93K | $0 | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARCH VENTURE PARTNERS X LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BRUDNICK RICHARD |
Officer | 20.00K | Purchase |
GOTTESDIENER KEITH MICHAEL |
Chief Executive Officer | — | Stock Gift |
GV 2021 GP, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
LEE ANN LOUISE |
Officer | 100.00K | Purchase |
LIU DAVID R |
Beneficial Owner of more than 10% of a Class of Security | 20.24M | Purchase |
NELSEN ROBERT TAYLOR |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
REINE ALLAN |
Chief Executive Officer | 125.00K | Purchase |
Fundamentals
Market cap$634.82M
Enterprise value$640.07M
Revenue (TTM)$4.07M
Gross profit$-142.13M
EBITDA$-189.12M
Net income$-187.89M
EPS (TTM)$-1.07
Free cash flow$-75.78M
Total cash$95.07M
Total debt$112.48M
Book value / share$0.23
Shares outstanding181.38M
Float112.25M
Short % of float22.65%
Dividend yield0.00%
Beta (5Y)2.38
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.94
PEG ratio—
Price / sales—
Price / book15.56
EV / revenue157.15
EV / EBITDA-3.38
Gross margin0.00%
Operating margin-3750.87%
Profit margin0.00%
Return on equity-373.29%
Return on assets-46.52%
Debt / equity282.54
Current ratio3.06
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.63M | $2.98M | $0 | $0 | — | +55.3% |
| Operating revenue | $4.63M | $2.98M | $0 | $0 | — | +55.3% |
| Research & development | $160.64M | $155.29M | $147.91M | $86.72M | — | +3.4% |
| Selling, general & admin | $52.35M | $50.16M | $43.39M | $29.82M | — | +4.4% |
| Total operating expense | $212.98M | $205.45M | $191.29M | $116.54M | — | +3.7% |
| Operating income | -$208.35M | -$202.47M | -$191.29M | -$116.54M | — | -2.9% |
| Net interest income | $4.15M | $3.52M | $2.81M | — | — | +17.8% |
| Pre-tax income | -$201.14M | -$195.88M | -$198.41M | -$122.77M | — | -2.7% |
| Tax provision | — | $0 | -$279.00K | -$948.00K | -$486.00K | — |
| Net income | -$201.14M | -$195.88M | -$198.13M | -$121.82M | — | -2.7% |
| Net income to common | -$201.14M | -$195.88M | -$198.13M | -$142.01M | — | -2.7% |
| Basic EPS | -1.35 | -1.65 | -2.18 | -4.19 | — | +18.2% |
| Diluted EPS | -1.35 | -1.65 | -2.18 | -4.19 | — | +18.2% |
| EBIT | -$208.35M | -$202.47M | -$191.29M | -$116.54M | — | -2.9% |
| EBITDA | -$201.03M | -$196.34M | -$186.64M | -$114.32M | — | -2.4% |
| Basic shares | 148.76M | 118.60M | 90.97M | 33.89M | — | +25.4% |
| Diluted shares | 148.76M | 118.60M | 90.97M | 33.89M | — | +25.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $63.03M | $182.48M | $41.57M | $187.62M | -65.5% |
| Cash & short-term investments | $177.68M | $190.44M | $121.67M | $293.92M | -6.7% |
| Total current assets | $181.29M | $211.89M | $142.98M | $296.62M | -14.4% |
| Property, plant & equipment | $146.75M | $71.56M | $36.60M | $48.55M | +105.1% |
| Total assets | $342.73M | $297.51M | $193.85M | $360.31M | +15.2% |
| Total current liabilities | $37.45M | $37.96M | $56.42M | $26.71M | -1.4% |
| Total debt | $116.43M | $40.79M | $13.63M | $28.75M | +185.4% |
| Total liabilities | $221.87M | $144.36M | $60.78M | $44.04M | +53.7% |
| Retained earnings | -$888.35M | -$687.21M | -$491.33M | -$293.20M | -29.3% |
| Shareholder equity | $120.87M | $153.15M | $133.07M | $316.27M | -21.1% |
| Working capital | $143.84M | $173.93M | $86.55M | $269.90M | -17.3% |
| Net tangible assets | $120.87M | $153.15M | $133.07M | $316.27M | -21.1% |
| Shares issued | 180.51M | 131.16M | 97.38M | 97.21M | +37.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$201.14M | -$195.88M | -$198.13M | -$121.82M | -2.7% |
| Depreciation & amortisation | $7.32M | $6.13M | $4.65M | $2.22M | +19.5% |
| Stock-based compensation | $29.27M | $26.07M | $13.91M | $6.46M | +12.3% |
| Change in working capital | -$5.34M | $31.08M | $2.65M | -$35.40M | -117.2% |
| Operating cash flow | -$162.56M | -$122.86M | -$165.41M | -$131.83M | -32.3% |
| Capital expenditure | -$4.53M | -$7.29M | -$8.72M | -$16.09M | +37.9% |
| Investing cash flow | -$108.76M | $68.46M | $18.71M | -$47.10M | -258.9% |
| Financing cash flow | $151.51M | $195.88M | $655.00K | $181.49M | -22.6% |
| Free cash flow | -$167.09M | -$130.16M | -$174.14M | -$147.92M | -28.4% |
| End cash position | $76.72M | $196.54M | $55.07M | $201.12M | -61.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.15M | $856.00K | $838.00K | $1.23M | $1.11M | — | +34.8% |
| Operating revenue | $1.15M | $856.00K | $838.00K | $1.23M | $1.11M | — | +34.8% |
| Research & development | $33.40M | $34.10M | $34.71M | $43.99M | $41.38M | — | -2.1% |
| Selling, general & admin | $11.04M | $17.41M | $14.74M | $11.21M | $13.12M | — | -36.6% |
| Total operating expense | $44.44M | $51.51M | $49.45M | $55.20M | $54.49M | — | -13.7% |
| Operating income | -$43.28M | -$50.65M | -$48.61M | -$53.97M | -$53.38M | — | +14.5% |
| Net interest income | $788.00K | $1.02M | $1.08M | $1.14M | $743.00K | — | -22.8% |
| Pre-tax income | -$42.11M | -$49.12M | -$46.08M | -$50.58M | -$52.59M | — | +14.3% |
| Tax provision | — | — | — | — | $0 | $0 | — |
| Net income | -$42.11M | -$49.12M | -$46.08M | -$50.58M | -$52.59M | — | +14.3% |
| Net income to common | -$42.11M | -$49.12M | -$46.08M | -$50.58M | -$52.59M | — | +14.3% |
| Basic EPS | -0.24 | -0.28 | — | -0.32 | -0.41 | -0.40 | +14.3% |
| Diluted EPS | -0.24 | -0.28 | — | -0.32 | -0.41 | -0.40 | +14.3% |
| EBIT | -$43.28M | -$50.65M | -$48.61M | -$53.97M | -$53.38M | — | +14.5% |
| EBITDA | -$41.50M | -$48.80M | -$46.73M | -$52.09M | -$51.51M | — | +15.0% |
| Basic shares | 177.22M | 177.10M | — | 160.50M | 129.19M | 130.88M | +0.1% |
| Diluted shares | 177.22M | 177.10M | — | 160.50M | 129.19M | 130.88M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $47.45M | $64.11M | $63.03M | $71.40M | $53.80M | — | -26.0% |
| Cash & short-term investments | $47.45M | $135.50M | $177.68M | $213.29M | $101.75M | — | -65.0% |
| Total current assets | $96.80M | $137.89M | $181.29M | $231.41M | $121.29M | — | -29.8% |
| Property, plant & equipment | — | $142.15M | $146.75M | $139.91M | $144.03M | $150.34M | — |
| Total assets | $249.04M | $294.73M | $342.73M | $385.01M | $279.01M | — | -15.5% |
| Total current liabilities | $31.69M | $36.29M | $37.45M | $35.02M | $34.11M | — | -12.7% |
| Total debt | $112.48M | $114.51M | $116.43M | $118.14M | $119.74M | — | -1.8% |
| Total liabilities | $209.23M | $218.03M | $221.87M | $223.19M | $218.15M | — | -4.0% |
| Retained earnings | $979.59M | -$937.48M | -$888.35M | -$842.27M | -$791.69M | — | +204.5% |
| Shareholder equity | $2.00B | $76.70M | $120.87M | $161.82M | $60.86M | — | +2,506.2% |
| Working capital | $65.11M | $101.60M | $143.84M | $196.39M | $87.18M | — | -35.9% |
| Net tangible assets | $2.00B | $76.70M | $120.87M | $161.82M | $60.86M | — | +2,506.2% |
| Shares issued | 180.74M | 180.62M | 180.51M | 180.31M | 134.49M | — | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$42.11M | -$49.12M | -$46.08M | -$50.58M | -$52.59M | +14.3% |
| Depreciation & amortisation | $1.78M | $1.86M | $1.88M | $1.88M | $1.86M | -3.8% |
| Stock-based compensation | $4.87M | $4.64M | $4.51M | $12.75M | $6.33M | +4.8% |
| Change in working capital | -$8.14M | -$2.50M | $1.16M | $609.00K | $548.00K | -225.6% |
| Operating cash flow | -$41.05M | -$42.71M | -$37.26M | -$35.04M | -$41.41M | +3.9% |
| Capital expenditure | -$46.00K | -$214.00K | -$290.00K | -$247.00K | -$1.57M | +78.5% |
| Investing cash flow | $24.03M | $43.39M | $28.33M | -$92.12M | $2.77M | -44.6% |
| Financing cash flow | $361.00K | $393.00K | $562.00K | $144.75M | $197.00K | -8.1% |
| Free cash flow | -$41.09M | -$42.92M | -$37.55M | -$35.29M | -$42.98M | +4.3% |
| End cash position | $61.14M | $77.80M | $76.72M | $85.09M | $67.50M | -21.4% |
Options analytics
Put / call volume
0.19
Call-heavy session
Put / call open interest
5.37
Positioning, not flow
Max pain
8.00
+128.6% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
2.17K
Contracts, this expiry
Put volume
405
Contracts, this expiry
Heaviest call OI
8.00
35 contracts
Heaviest put OI
2.00
156 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.26 | -0.24 | +6.0% |
| Mar 2026 | -0.25 | -0.28 | -12.6% |
| Dec 2025 | -0.26 | -0.24 | +6.9% |
| Sep 2025 | -0.25 | -0.32 | -29.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.23 | 13 | $1.10M | -10.6% |
| Next quarter | -0.22 | 13 | $6.46M | +670.8% |
| Current year | -0.94 | 14 | $8.83M | +90.7% |
| Next year | -0.89 | 12 | $10.55M | +19.5% |
Analyst targets & ownership
Mean target$7.11
High target$11.00
Low target$4.25
Implied upside108.23%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold3
Sell / Strong sell0 / 0
Held by insiders20.30%
Held by institutions71.00%
Institutions holding254
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.08
+10.92% from price
SMA 20
3.15
+11.01% from price
SMA 50
3.24
+8.11% from price
SMA 100
3.25
+5.07% from price
SMA 200
3.48
+0.68% from price
EMA 12
3.16
+8.03% from price
EMA 26
3.20
+6.61% from price
EMA 50
3.25
+5.21% from price
RSI (14)
58.2
Neutral
MACD (12,26,9)
-0.04
Hist 0.03
ATR (14)
0.28
8.03% of price
Realised vol 30D
82.7%
Annualised
Bollinger upper
3.52
20, 2σ
Bollinger lower
2.79
20, 2σ
50 / 200 cross
Death
3.24 vs 3.48
Trend bias
Above 200
+0.68%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.29
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
82.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.1%
Peak to trough
Max drawdown 5Y
-94.6%
Peak to trough
ATR 14
0.28
8.03% of price
Beta (reported)
2.38
5Y monthly, from filing
Short interest
Shares short
32.13M
Prior 35.02M
Change vs prior
-8.3%
Shorts covering
% of float
22.65%
Heavily shorted
% of shares out
17.72%
Against total outstanding
Days to cover
11.7
Crowded exit
Float
112.25M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 25, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 19, 26 | BMO Capital | INITIATED | Outperform | Outperform |
| Aug 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 29, 26 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Mar 12, 26 | Oppenheimer | INITIATED | — | Outperform |
| Dec 23, 25 | LifeSci Capital | INITIATED | — | Outperform |
| Nov 11, 25 | Citigroup | MAINTAINED | Neutral | Neutral |
| Nov 10, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 12, 25 | Citigroup | MAINTAINED | Neutral | Neutral |
| Aug 8, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| May 27, 25 | Citigroup | DOWNGRADE | Buy | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-08
Corporate Changes & Voting Matters
8-K · 2026-06-08
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-04-16
Post-effective amendment to a registration statement that is not immediately effective upon filing
POS AM · 2026-03-03
Corporate Changes & Voting Matters
8-K · 2026-01-12
Headlines
Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
MT Newswires · 2d ago
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
GlobeNewswire · 2d ago
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Barchart · 8d ago
Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says
MT Newswires · 12d ago
Prime Medicine stock surges on FDA IND clearance
Investing.com · 13d ago
Prime Medicine Says US FDA Clears PM647 IND for Alpha-1 Antitrypsin Deficiency; Shares Rise After Hours
MT Newswires · 13d ago
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
GlobeNewswire · 13d ago
Anthropic AI Discovery Gene-Editing Stocks Falling
GuruFocus.com · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.